Drugs / Oxycodone nalaxone prolonged release tablets (OXN)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00412152 | Jan 2006 → Apr 2008 | — | Mundipharma Research GmbH & Co KG | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oxycodone nalaxone prolonged release tablets (OXN) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00412152 ↗ |
| Known as | OXN | “Oxycodone nalaxone prolonged release tablets (OXN)” NCT00412152 ↗ |
| Route | Oral | “an oral fixed-ratio combination of oxycodone prolonged-release (PR) and naloxone PR compared with oxycodone PR in relieving opioid-induced constipation.” PMID 19032132 ↗ Dec 2008 |